Compounds > 3-(3,5-dichlorophenyl)-1-methyl-2,5-pyrrolidinedione
Page last updated: 2024-09-04

3-(3,5-dichlorophenyl)-1-methyl-2,5-pyrrolidinedione and Alzheimer Disease

3-(3,5-dichlorophenyl)-1-methyl-2,5-pyrrolidinedione has been researched along with Alzheimer Disease in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Altomare, D; Barkhof, F; Berkhof, J; Bouwman, F; Caprioglio, C; Collij, LE; Delrieu, J; Demonet, JF; Drzezga, A; Edison, P; Farrar, G; Frisoni, GB; Garibotto, V; Gismondi, R; Gispert, JD; Grau-Rivera, O; Hitzel, A; Jelic, V; Jessen, F; Lopes Alves, I; Molinuevo, JL; Moro, C; Nordberg, A; Payoux, P; Saint-Aubert, L; Savitcheva, I; Scheltens, P; Stephens, AW; van Maurik, IS; Walker, Z; Zeyen, P1
Baldwin, T; Beck, D; Bourgeat, P; Faux, NG; Fedyashov, V; Fripp, J; Goudey, B; Masters, CL; Saint-Jalmes, M1

Trials

1 trial(s) available for 3-(3,5-dichlorophenyl)-1-methyl-2,5-pyrrolidinedione and Alzheimer Disease

ArticleYear
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical Trial.
    JAMA neurology, 2023, 06-01, Volume: 80, Issue:6

    Topics: Aged; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Amyloidogenic Proteins; Brain; Cognitive Dysfunction; Female; Humans; Male; Positron-Emission Tomography; Prospective Studies

2023

Other Studies

1 other study(ies) available for 3-(3,5-dichlorophenyl)-1-methyl-2,5-pyrrolidinedione and Alzheimer Disease

ArticleYear
Disease progression modelling of Alzheimer's disease using probabilistic principal components analysis.
    NeuroImage, 2023, Volume: 278

    Topics: Alzheimer Disease; Biomarkers; Cognitive Dysfunction; Cross-Sectional Studies; Disease Progression; Humans; Magnetic Resonance Imaging; Neuroimaging

2023